Abstract
Psoriatic arthritis (PsA) is an inflammatory arthritis, characterized by mild arthralgia to severe joint deformities. Long term management of these diseases with nonsteroidal anti-inflammatory drugs (NSAIDs) and diseasemodifying antirheumatic drugs (DMARDs) is limited due to lack of efficacy and potential organ toxicity. Recently, the approval of injectable biologics, such as T cell inhibitors and TNF-α antagonist, has changed the treatment of moderateto- severe psoriasis and PsA. Unlike NSAIDs and DMARDs, TNF-α antagonists not only provide unambiguous benefits for the skin and joints, but also prevent the progression of structural damage in peripheral joints. Biological agents in the treatment of PsA have broad prospects. More and more biological agents are being developed for the treatment of PsA. In the current review, we will discuss the progress of biological agents on PsA.
Keywords: Biotherapy, psoriatic arthritis, T-cell modulating agents, TNF-α inhibitors.
Current Pharmaceutical Biotechnology
Title:Progress of Biological Agents on Psoriatic Arthritis
Volume: 15 Issue: 6
Author(s): Yan Li, Dashan Wang, Yantang Wang and Guixiu Shi
Affiliation:
Keywords: Biotherapy, psoriatic arthritis, T-cell modulating agents, TNF-α inhibitors.
Abstract: Psoriatic arthritis (PsA) is an inflammatory arthritis, characterized by mild arthralgia to severe joint deformities. Long term management of these diseases with nonsteroidal anti-inflammatory drugs (NSAIDs) and diseasemodifying antirheumatic drugs (DMARDs) is limited due to lack of efficacy and potential organ toxicity. Recently, the approval of injectable biologics, such as T cell inhibitors and TNF-α antagonist, has changed the treatment of moderateto- severe psoriasis and PsA. Unlike NSAIDs and DMARDs, TNF-α antagonists not only provide unambiguous benefits for the skin and joints, but also prevent the progression of structural damage in peripheral joints. Biological agents in the treatment of PsA have broad prospects. More and more biological agents are being developed for the treatment of PsA. In the current review, we will discuss the progress of biological agents on PsA.
Export Options
About this article
Cite this article as:
Li Yan, Wang Dashan, Wang Yantang and Shi Guixiu, Progress of Biological Agents on Psoriatic Arthritis, Current Pharmaceutical Biotechnology 2014; 15 (6) . https://dx.doi.org/10.2174/138920101506140910150227
DOI https://dx.doi.org/10.2174/138920101506140910150227 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Emerging Therapies in Relapsing-Remitting Multiple Sclerosis
Reviews on Recent Clinical Trials Acute Appendicitis as a Manifestation of the Immune Reconstitution Inflammatory Syndrome
Current HIV Research Therapeutic Strategies in Autoimmune Diseases by Interfering with Leukocyte Endothelium Interaction
Current Pharmaceutical Design Angiogenesis as a therapeutic target in breast cancer
Mini-Reviews in Medicinal Chemistry Survey of Latin American Neuroimmunologists on the Treatment of Multiple Sclerosis with Monoclonal Antibodies
Current Drug Safety Nonstandard Drugs and Feasible New Interventions for Autoimmune Hepatitis: Part II
Inflammation & Allergy - Drug Targets (Discontinued) Therapeutic Monitoring of Immunotherapies in Autoimmune Diseases
Current Pharmaceutical Design Antibodies as Crypts of Antiinfective and Antitumor Peptides
Current Medicinal Chemistry Anti-VEGF Anticancer Drugs: Mind the Hypertension
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Current Options in the Treatment of Mitochondrial Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Anti-HIV Drug Distribution to the Central Nervous System
Current Pharmaceutical Design Advances in Antioxidative Therapy of Multiple Sclerosis
Current Medicinal Chemistry Neuro-AIDS: Current Status and Challenges to Antiretroviral Drug Therapy (ART) for Its Treatment
Current Drug Therapy Targeted Radiotherapy for Malignant Gliomas
Current Drug Discovery Technologies Genetic and Environmental Factors in Complex Neurodevelopmental Disorders
Current Genomics Sorafenib Decreases Extrahepatic Collaterals in Hepatocellular Carcinoma: Implication of the Synergistic Effect of Sorafenib and Transcatheter Chemoembolization
Current Medical Imaging Disease Progression in HIV Late Presenters: the Role of HIV Clinical Indicator Diseases Prior to HIV Diagnosis
Current HIV Research Regulation of Angiogenesis by the Small Heat Shock Protein αB-Crystallin
Current Angiogenesis (Discontinued) Challenges in Diagnosing Cerebral Lacunar Infarcts
Current Medical Imaging Pediatric Cutaneous Graft Versus Host Disease: A Review
Current Pediatric Reviews